CRISPR Therapeutics AG (CRSP): Price and Financial Metrics


CRISPR Therapeutics AG (CRSP)

Today's Latest Price: $58.33 USD

1.30 (-2.18%)

Updated Jan 17 4:00pm

Add CRSP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 322 in Biotech

See all "A" rated Strong Buy stocks

CRSP Stock Summary

  • Price to trailing twelve month operating cash flow for CRSP is currently 132.16, higher than 97.4% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 15.49, CRISPR Therapeutics AG has a higher such ratio than 92.4% of stocks in our set.
  • Revenue growth over the past 12 months for CRISPR Therapeutics AG comes in at 501.94%, a number that bests 98.61% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to CRSP, based on their financial statements, market capitalization, and price volatility, are VYGR, SRRK, JNCE, SPRO, and CANF.
  • Visit CRSP's SEC page to see the company's official filings. To visit the company's web site, go to crisprtx.com.
CRSP Daily Price Range
CRSP 52-Week Price Range

CRSP Stock Price Chart More Charts


CRSP Price/Volume Stats

Current price $58.33 52-week high $74.00
Prev. close $59.63 52-week low $29.34
Day low $57.81 Volume 1,116,590
Day high $60.28 Avg. volume 1,136,858
50-day MA $62.79 Dividend yield N/A
200-day MA $48.39 Market Cap 3.22B

CRISPR Therapeutics AG (CRSP) Company Bio


CRISPR Therapeutics AG focuses on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. The company is based in Basel, Switzerland.





CRSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CRSP Latest Social Stream


Loading social stream, please wait...

View Full CRSP Social Stream

CRSP Price Returns

1-mo -10.80%
3-mo 53.86%
6-mo 18.94%
1-year 62.57%
3-year 171.30%
5-year N/A
YTD -4.23%
2019 113.18%
2018 21.68%
2017 15.89%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7477 seconds.